Publishing of Orion Corporation's Interim Report for January-March 2014 on 29 April 2014

        Print
| Source: Orion
ORION CORPORATION     STOCK EXCHANGE RELEASE   22 APRIL 2014 at 10:45 A.M. EEST


Publishing of Orion Corporation's Interim Report for January-March 2014 on 29
April 2014



Orion will publish its Interim Report for January-March 2014 on Tuesday, 29
April 2014 approximately at 12:00 Finnish time (EEST). The release and related
presentation material in Finnish and in English will be available on the Group's
homepage at www.orion.fi/en/investors promptly after the publishing.

News conference for analysts and media on Tuesday 29 April 2014 at 13:30 EEST

A news conference for analysts and media will be held on Tuesday 29 April 2014
at 13:30 EEST at Hotel Kämp, address Pohjoisesplanadi 29, Helsinki. President
and CEO Timo Lappalainen will give a brief presentation in English on the
financial review.

Live webcast and conference call

The event can be followed live as a webcast accessible at
http://qsb.webcast.fi/o/orion/orion_2014_0429_q1.

Questions can be asked also through conference call lines after the result
presentation. The conference call ID is 943080 and the phone numbers to
participate the conference are:

when calling from the United States             +1 334 323 6201
when calling from other countries                +44 (0)20 7162 0025

News conference recordings

A recording of the event in English and a recording of the presentation by the
President and CEO in Finnish will be available on the Orion website later the
same day.

Silent period

The silent period preceding the publication is ongoing and continues until the
disclosure.


Orion Corporation



 Timo Lappalainen  Jari Karlson
 President and CEO CFO



Publisher:
Orion Corporation
www.orion.fi/en


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2013 amounted to EUR 1,007 million and the company had
about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.

[HUG#1778560]